On the whole, even taking into consideration the limitations of a post hoc analysis of a subgroup of patients treated across different cancer centers, our experience with the above reported modified schedule of lapatinib–capecitabine regimen in HER2 positive advanced breast cancer patients can be considered a very satisfactory experience, with encouraging treatment efficacy results and, above all, an optimal quality of life in the treated patients. This evidence concerns the gene ERBB2 and breast cancer.